Canopy Growth Faces a Defining August: Nasdaq Compliance and Investor Confidence Hang in the Balance
Published on 07/22/2026 at 06:22 | Redaktion boerse-global.de
Canopy Growth is heading into a pivotal stretch this month, with its stock hovering dangerously close to a 52-week low and a key investor conference offering management a rare chance to reset the narrative. The cannabis company, listed on both the TSX as WEED and the Nasdaq as CGC, has confirmed its participation in the 46th Canaccord Genuity Growth Conference in Boston, running from August 11 to 13. CEO Luc Mongeau is scheduled to present on the opening day at 12:00 p.m. local time, with a webcast available for investors outside the conference circuit.
The timing could hardly be more critical. Canopy's shares closed at €0.8260, shedding 1.10% in the prior session, and now sit just over 10% above their 52-week trough of €0.75, which was touched in late March. The stock has lost 20.73% since the start of the year and trades a staggering 58.66% below its December 2025 peak of €2.00. Compounding the technical weakness, the share price is roughly 15% beneath its 200-day moving average of €0.9786, underscoring a persistent medium-term downtrend.
The Nasdaq Threshold Looms Large
What makes the current price level especially fraught is its proximity to the $1.00 threshold required for continued listing on the Nasdaq. While no formal reverse-split announcement has been made, market participants are openly discussing the scenario. If the stock's U.S. dollar equivalent trades below $1.00 for 30 consecutive trading days, the exchange would issue a deficiency notice, giving Canopy 180 days to regain compliance. A reverse stock split would be the conventional remedy — the company last took that route in December 2023. Historically, such consolidations at Canopy have been followed by further declines rather than a durable recovery, a pattern that adds to the unease.
The 50-day moving average of €0.8706 now serves as a critical near-term gauge. A sustained move above that level could ease the Nasdaq anxiety, while a continued slide toward new lows would make a formal exchange notice and subsequent reverse split increasingly probable in the months ahead.
Should investors sell immediately? Or is it worth buying Canopy Growth?
Medical Cannabis Provides a Counter-Narrative
Amid the technical pressure, there are genuine operational bright spots that supporters of a turnaround point to. For fiscal 2026, revenue rose 5.80% to 284.60 million Canadian dollars, while the net loss from continuing operations narrowed by roughly 49% to 262.91 million Canadian dollars. The medical cannabis segment has been the standout performer: it grew 27% in the fourth quarter and 17% for the full year, establishing itself as a reliable growth engine within the Canadian core business.
The balance sheet has also undergone meaningful repair. Canopy raised 374.2 million Canadian dollars in equity during fiscal 2026 and ended the year with net liquidity of 131.3 million Canadian dollars, a sharp reversal from the net debt position it carried the prior year. If the stock can stabilize above the 50-day average and the medical segment maintains its momentum, the reverse-split scenario could recede.
Headwinds in Recreational and International Operations
The bullish case, however, faces substantial counterarguments. The recreational cannabis segment, while up 20% for the full year, showed a marked deceleration in the fourth quarter, raising questions about the sustainability of that growth. International operations have been equally uneven: net cannabis revenue from outside Canada surged 68% in the fourth quarter but still ended the full year down 7% year-over-year, with supply constraints hampering performance across several markets.
Profitability has also deteriorated. Gross margin fell by roughly 4 to 5 percentage points in the fourth quarter and by about 6 points for the full year. Persistent net losses and a continued reliance on equity issuance leave the balance sheet vulnerable, even after the recent improvement. The combination of a slowing Canadian recreational business, erratic international results, and shrinking margins provides ample ammunition for caution.
Canopy Growth at a turning point? This analysis reveals what investors need to know now.
What to Watch in Boston
Analyst sentiment is currently mixed. Expectations for the upcoming quarter point to an improvement in earnings per share of roughly 71% compared to the same period last year — a striking figure on a percentage basis. Yet those same analysts have been trimming their estimates over the past month, suggesting that optimism about growth rates is tempered by reality. This tension between high relative improvement and lowered absolute forecasts defines the current market mood.
For investors, Mongeau's appearance at the Canaccord conference on August 11 will be a critical test. If he delivers concrete details on the strategic sharpening that has been hinted at in recent weeks, it could shift the cautious market perception. Until then, the stock remains caught between operational progress and technical distress, with annualized volatility running above 35%. The next few weeks will determine whether the medical cannabis strength and balance sheet repair can outweigh the Nasdaq compliance risk — or whether the reverse-split debate moves from speculation to inevitability.
Ad
Canopy Growth Stock: New Analysis - 22 July
Fresh Canopy Growth information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
